Enveric Biosciences Secures New U.S. Patent for Drug Candidates

Got story updates? Submit your updates here. ›

Enveric Biosciences, a biopharmaceutical company focused on developing next-generation psychedelic-inspired medicines, has secured a new U.S. patent for its EVM301 series of drug candidates. The patent provides intellectual property protection for the company's novel compounds, which are being developed as potential treatments for a range of neurological and psychiatric disorders.

Why it matters

This patent represents an important milestone for Enveric as it works to advance its pipeline of psychedelic-inspired therapies. The EVM301 series is a key part of the company's drug development efforts, and this patent helps solidify its position in the emerging psychedelics-based medicine market.

The details

The newly issued U.S. patent covers the chemical composition and methods of use for the EVM301 series of drug candidates developed by Enveric. These compounds are based on the molecular structure of psychedelic substances but have been engineered to enhance therapeutic effects while minimizing potential side effects. Enveric is exploring the use of the EVM301 series for indications such as treatment-resistant depression, anxiety disorders, and chronic pain.

• The patent was issued by the U.S. Patent and Trademark Office on March 31, 2026.

What’s next

Enveric plans to continue advancing the EVM301 series through preclinical and clinical development, with the goal of eventually bringing these novel psychedelic-inspired therapies to market.